Vaccines

Novavax Launches Phase I Trial of Bird-Flu Vaccine

The company has launched a second Phase I clinical trial of a vaccine designed to prevent a bird-flu pandemic.

Novavax, Inc. announced today that it has begun enrollment in a second Phase I clinical trial of its monovalent virus-like particle (VLP) vaccine candidate to prevent potential pandemic disease due to A/H5N1 avian influenza viruses ("bird flu"). This randomized, observer-blind, dose-ranging, placebo-controlled trial is being conducted under the company's contract with the U.S.

No votes yet

Crucell N.V. (NL) - Crucell Reaches Agreement with Sanofi Pasteur on Programs in the Field of Paediatric and Respiratory Vaccines

Leiden, the Netherlands (July 8, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Crucell and sanofi pasteur reached an agreement on a series of transactions to restructure their long standing partnership.

Syndicate content